EffRx, Inc. is a drug delivery company that
utilizes value-added drug delivery technologies to improve
the performance of established pharmaceuticals.
The Company applies its technologies to well established,
proven compounds to develop reformulated products with
reduced gastrointestinal side effects, better absorption,
and faster onset of action. EffRx develops novel
prescription and OTC pharmaceuticals at relatively low
development cost and risk, shorter time to market and with
premium pricing compared with generics.
The Company exploits a number of drug delivery technologies,
notably soluble effervescent formulations, granules for
immediate dispersion, and fast-melt lozenges with an
effervescent layer. These technologies are applied to
established high volume drugs with large market potential
in various therapeutic areas. The Company's lead products
are focused on the treatment of osteoporosis, xerostomia
(dry mouth), and pain.
EffRx currently has an extensive pipeline of product
candidates, with three products in active development.
The most advanced product is effervescent alendronate for
the treatment of osteoporosis, which is being developed and
commercialized in partnership with Generics UK Limited, a
division of Merck KGaA. Also in active development are a
bi-layer tablet for the treatment of xerostomia and a
product for pain. EffRx is also in partnership discussions
for several other products. |
